---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-254619"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:40:22.510987+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end

## Summary
- Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
- Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.
- 12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.
- Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.
- Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025.

## SEC filing metadata
- accession: 0001193125-25-254619
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/0001193125-25-254619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/fulc-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-254619
- JSON: https://secwatch.observer/filing/0001193125-25-254619.json
- Plain text: https://secwatch.observer/filing/0001193125-25-254619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.